Études pharmaco-épidémiologiques : quels niveaux de preuve et comment les atteindre ?

Le Gales, 2003, Postmarketing evaluation of drugs. Actual efficacy, population exposed and impact on public health, Therapie, 58, 209 Vray, 2005, The respective roles of controlled clinical trials and cohort monitoring studies in the pre- and postmarketing assessment of drugs, Therapie, 60, 339, 10.2515/therapie:2005047 Tubach, 2011, Role of the post-marketing authorisation studies in drug risk surveillance: specifications and methodologies, Therapie, 66, 355, 10.2515/therapie/2011048 Gueyffier, 2012, Contribution of modeling approaches and virtual populations in transposing the results of clinical trials into real life and in enlightening public health decisions, Therapie, 67, 367, 10.2515/therapie/2012042 Hill, 1965, The environment and disease: association or causation?, Proc R Soc Med, 58, 295 Haute autorité de santé Trans Durieux, 2011, Table des niveaux de preuves du Centre d’Evidence Based Medicine d’Oxford (OCEBM Levels of Evidence Working Group) Balshem, 2011, GRADE guidelines: 3. Rating the quality of evidence, J Clin Epidemiol, 64, 401, 10.1016/j.jclinepi.2010.07.015 Howick, 2009, The evolution of evidence hierarchies: what can Bradford Hill’s ‘guidelines for causation’ contribute?, J R Soc Med, 102, 186, 10.1258/jrsm.2009.090020 Howick, 2010, Evidence-based mechanistic reasoning, J R Soc Med, 103, 433, 10.1258/jrsm.2010.100146 Wald, 2003, Teleoanalysis: combining data from different types of study, BMJ, 327, 616, 10.1136/bmj.327.7415.616 Loke, 2007, Systematic reviews of adverse effects: framework for a structured approach, BMC Med Res Methodol, 7, 32, 10.1186/1471-2288-7-32 Singh, 2007, Thiazolidinediones and heart failure: a teleoanalysis, Diabetes Care, 30, 2148, 10.2337/dc07-0141 Edwards, 2000, Adverse drug reactions: definitions, diagnosis, and management, Lancet, 356, 1255, 10.1016/S0140-6736(00)02799-9 Blake, 2012, Increasing scientific standards, independence and transparency in post-authorisation studies: the role of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance, Pharmacoepidemiol Drug Saf, 21, 690, 10.1002/pds.3281 Blake, 2011, European Medicines Agency review of post-authorisation studies with implications for the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance, Pharmacoepidemiol Drug Saf, 20, 1021, 10.1002/pds.2209 Berger, 2012, Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force report, Value Health, 15, 217, 10.1016/j.jval.2011.12.010 Stamenkovic, 2012, French Health Authority (HAS) Guidance: the post-registration studies on health technologies (drugs, medical devices and instruments): principles and methods, Therapie, 67, 409, 10.2515/therapie/2012065